SlideShare a Scribd company logo
Cardiovascular and
Cerebrovascular health
in the management of
hypertensive patients
Not all ARBs looks
after your patient
heart as well as
his mind
Cardiovascular Disease: A Worldwide Epidemic
World Health Organization Burden of Disease Estimates 2002.
0 5 10 15 20 25 30 35 40 45 50
CVDs
Infectious/parasitic diseases
Malignant neoplasms
Respiratory infections
Respiratory diseases
Unintentional injuries
Perinatal conditions
Digestive diseases
Intentional injuries
Neuropsychiatric conditions
Diabetes mellitus
Cause of death
Worldwide
Developed world
CVD is responsible for one third of all deaths worldwide and almost half of all
deaths in the developed world
Contribution of Risk Factors to Burden of
Disease Mortality*
*Based on The World Health Report 2003.*Based on The World Health Report 2003.
Yach et al.Yach et al. JAMAJAMA. 2004;291:2616-2622.. 2004;291:2616-2622.
0 5 10 15 20
Percentage of Mortality Attributable to Risk Factors
DevelopingDeveloping
countriescountries
DevelopedDeveloped
countriescountries
Blood pressureBlood pressure
TobaccoTobacco
UnderweightUnderweight
AlcoholAlcohol
CholesterolCholesterol
Unsafe sexUnsafe sex
OverweightOverweight
Unsafe water, sanitation,Unsafe water, sanitation,
hygienehygiene
Low fruit and vegetableLow fruit and vegetable
intakeintake
Indoor smoke from solid fuelsIndoor smoke from solid fuels
Physical inactivityPhysical inactivity
Hypertension: A Growing Problem
Prevalence (%)
United StatesUnited States77
EgyptEgypt99
JapanJapan88
ItalyItaly77
SwedenSweden77
EnglandEngland77
SpainSpain77
FinlandFinland77
GermanyGermany77
00 1010 2020 3030 4040 5050
TaiwanTaiwan99
CanadaCanada77
South KoreaSouth Korea99
*Defined as systolic/diastolic blood pressure*Defined as systolic/diastolic blood pressure ≥≥140/90, (140/90, (≥≥160/95 for Taiwan)160/95 for Taiwan) or receiving treatment.or receiving treatment.
††
South Korea is defined as men, aged 30 to 59.South Korea is defined as men, aged 30 to 59.
7. Wolf-Maier et al.7. Wolf-Maier et al. JAMAJAMA. 2003;289:2363-2369; 8. Data on file. Pfizer Inc, New York, NY;. 2003;289:2363-2369; 8. Data on file. Pfizer Inc, New York, NY;
9.9. WHO Collaborating Centre on Surveillance of Cardiovascular Disease Web site. Available at: www.cvdinfobase.ca. Accessed February 22, 2005.WHO Collaborating Centre on Surveillance of Cardiovascular Disease Web site. Available at: www.cvdinfobase.ca. Accessed February 22, 2005.
Lewington et al. Lancet 2002 ; 360 : 1903–13.
CARDIOVASCULAR MORTALITY DOUBLES FOR EVERY
INCREMENT IN SBP/DBP OF 20/10 mm Hg
 Meta-analysis of 61 prospective, observational studies
 1 million adults
 12.7 million person-years
BENEFITS OF BP DECREASE
Lewington S, et al. Lancet. 2002;360:1903-1913.
Effect of antihypertensive therapy on all
CV events: Comparison of more or less
intensive BP control
Relative risk (95% CIs)
1.0 1.25
More
intensive BP
control better
Less
intensive BP
control
better
0.5
Stroke
Coronary heart disease
Heart failure
Major CV events
CV death
Total mortality
BPLTTC Lancet 2003
Benefits of Lowering BP
Average Percent ReductionAverage Percent Reduction
Stroke incidenceStroke incidence 35–40%35–40%
Myocardial infarctionMyocardial infarction 20–25%20–25%
Heart failureHeart failure 50%50%
SBP-Associated Risks: MRFIT
Adapted from Neaton JD et al. Arch Intern Med. 1992;152:56-64.
SBP versus DBP in Risk of CHD Mortality
Diastolic BP
(mm Hg)
Systolic BP
(mm Hg)
CHD Death Rate
100+
90–99
80–89
75–79
70–74
<70 <120
120–139
140–159
160+
48.3
20.6
10.3
11.8
8.8
8.5
9.2
23.8
16.9
13.9
12.8
12.6
11.8
31.0
25.5
24.6 25.3
25.2
24.9
37.4
34.7
43.8
38.1
80.6
Pulse Pressure
• Increase in pulse pressure (PP) indicates
greater stiffness in large conduit arteries,
primarily the thoracic aorta.
• PP may be a better marker of increased
CV risk than either systolic BP or diastolic
BP alone in older persons.
PP = SBP – DBPPP = SBP – DBP
2007 ESH/ESC Hypertension Guidelines2007 ESH/ESC Hypertension Guidelines
First Choice Drug TreatmentFirst Choice Drug Treatment
 DiureticsDiuretics
 ACE-inhibitorsACE-inhibitors
 Calcium antagonistsCalcium antagonists
 Angiotensin receptor antagonistsAngiotensin receptor antagonists
 Beta-blockersBeta-blockers
Rationale for Use of ARB’s in
Hypertension
Rationale for Use of ARB’s in Hypertension
• Specific blockade of the renin-angiotensin-
aldosterone system provides:
– More complete blockade of BP response to angiotensin
II (specific for ATII receptor blockade)
– Reduced potential for target organ damage
– Reduced potential for bradykinin “cough”
– Best tolerability (specific for ATII receptor blockade)
– Some studies suggest a reduced risk of vascular events
compared with other BP lowering regimens
Guidelines recognize the additive positive effect of ARBs in hypertensives with:
• Type 2 diabetes
• End-organ disease, particularly that affecting the kidney
RR (95% CI)
Favors
ARB
Favors
Other
0.5 1.0 2.0
Relative risk
0.79 (0.69,0.90)Stroke
0.96 (0.85,1.09)CHD
Heart failure 0.84 (0.72,0.97)
Major CV events 0.90 (0.83,0.96)
CV death 0.96 (0.85,1.08)
Total mortality 0.94 (0.86,1.02)
Outcome
BP
difference
(mmHg)
-2/-1
-2/-1
-2/-1
-2/-1
-2/-1
-2/-1
Angiotensin Receptor Antagonists Reduce RiskAngiotensin Receptor Antagonists Reduce Risk
of Vascular Events And Total Mortalityof Vascular Events And Total Mortality
BPLTTC Lancet 2003; 362: 1527-35
Based on analysis of data from the SCOPE, IDNT, RENAAL and LIFE trials
Diuretics
β-blockers
Ca-antagonists
ACE-Inhibitors
LVMassreduction,%
-16
-14
-12
-10
-8
-6
-4
-2
0
- 8%
- 6%
- 11%
- 10% ARBs
- 13%
80 randomized controlled trials;
4113 patients
Meta-analysis of Randomized, Controlled Trials
of LV Hypertrophy Regression in Essential Hypertension
Klingbeil AU et al. Am J Med 2003; 115:41-46
ARBs significantly increased probability
of maintaining sinus rhythm
0
20
40
60
80
100
Probability
of maintaining
sinus rhythm (%)
ARB
+ amiodarone
Madrid A et al. Circulation
p = 0.008 vs. amiodarone
Amiodarone
85%
63%
159 patients with persistent atrial fibrillation were randomized159 patients with persistent atrial fibrillation were randomized
to either amiodarone or amiodarone + ARBto either amiodarone or amiodarone + ARB
Results are taken at 2-month follow-up visitResults are taken at 2-month follow-up visit
Mancia G et al. J Hypertens 2007; 25:1105-1187.
Antihypertensive treatment: Preferred drugs as
per new European guidelines
Clinical eventClinical event TreatmentTreatment
Atrial fibrillationAtrial fibrillation   
•RecurrentRecurrent Angiotensin receptor blockers, ACEAngiotensin receptor blockers, ACE
inhibitorsinhibitors
•PermanentPermanent Beta blockers, nonhydropyridineBeta blockers, nonhydropyridine
calcium antagonistscalcium antagonists
ESRD/proteinuriaESRD/proteinuria ACE inhibitors, angiotensin receptorACE inhibitors, angiotensin receptor
blockers, loop diureticsblockers, loop diuretics
PADPAD Calcium antagonistsCalcium antagonists
LVH=left ventricular hypertrophy
ESRD=end-stage renal disease
PAD=peripheral arterial disease
ISH=isolated systolic hypertension
ESH/ESC Guidelines
“A blocker of the renin-
angiotensin system should be
a regular component of
combination treatment and
the one preferred when
monotherapy is sufficient”
Others
2.2%
(-13.9%)
ACEi
26.9%
(-4.0%)
CCB
13.9%
(+4.8%)
DIU
15.7%
(+3.0%)
ARB
17.7%
(+17.9%)
BB
23.5%
(+9.1%)
Overall Hypertension Market in Egypt
ARBs are most rapidly growing group
Source: IMS Rx Audit MAT QIII’2007
HT Market Definition: C2, C3, C7, C8, C9
Teveten among other ARBs
Change in mean SBP and DBP from baseline after 8 weeks
of treatment with eprosartan (600mg/day) or placebo in
patients with mild-to-moderate hypertension
Eprosartan vs Placebo in Mild-to-Moderate HTN
-26
-17.1
-12.6 -13.5
-50
-45
-40
-35
-30
-25
-20
-15
-10
-5
0
mmHg
SBP
MBP
DBP
PP
Sega. Blood Press 1999;8:114
ReductioninsitSBP(mmHg)
p=0.025
–29.1
–21.2
–15
–25
–20
–30
0
–5
–10
ReductioninstaSBP(mmHg)
p=0.032
–27.8
–20.0
–15
–25
–20
–30
0
–5
–10
Eprosartan
Enalapril
Eprosartan reduces sitSBP and staSBP in
patients with severe hypertension
Argenziano & Trimarco. Curr Med Res Opin 1999;15:9
<65 years
(n=201)
≥65 years
(n=63)
0
–2
–4
–6
–8
–10
–12
–14
–16
–18
–20
MeanchangefrombaselineinsitSBP(mmHg)
Eprosartan has similar efficacy in young
and elderly patients
0
–2
–4
–6
–8
–10
–12
–14
–16
–18
–20
<65 years
(n=201)
≥65 years
(n=63)
MeanchangefrombaselineinsitDBP(mmHg)
Puig et al. J Hypertens 1999;17:1033
ReductioninsitBP(mmHg)
–18
–15
–12
–9
–6
–3
0
Diastolic Systolic
–12.4
–9.6
–12.7
–10.9
0
20
40
60
80
Responserate(%)
73
53
100
Eprosartan
Losartan
Eprosartan is more effective than losartan
in mild hypertension
PULSE PRESSURE REDUCTION
Robles NR, et al. Int J Clin Pract 2005;59(4):478-484
Reduction in mean pulse pressure, arterial pressure, SBP and DBP in
a 16-week open-label study (n=566)
Teveten effect on fibrinolytic/hemostatic
variables: Comparative study to losartan
In conclusion, the results indicate
that 6-month monotherapy with an
angiotensin II type 1 receptor blocker,
eprosartan, is associated with a more
favorable modification of hemostatic
& fibrinolytic status than with
losartan
Drugs Exp Clin Res. 2004;30(3):125-32
Effect of Teveten on cytoplasmic free calcium
mobilization, platelet activation, and
microparticle formation in hypertension
CONCLUSIONS: Teveten
significantly reduces blood
pressure and normalizes
undesirable changes in platelet
function
Am J Hypertens. 2004 Sep;17(9):757-63.
CEREBROVASCULAR RISK EPIDEMIOLOGY
Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and
stroke statistics—2009 update: a report from the American Heart Association Statistics
Committee and Stroke Statistics Subcommittee.Circulation 2009;119:e21–181.
 CVD is the 3rd
leading cause of death in the U.S. and the first
cause of long-term major disability
 There are 795,000 incident strokes in the U.S. each year
 8–12% of individuals die within the first 30 days of their initial
stroke
 Patients who survive the initial attack face an increased risk of
subsequent vascular events and stroke (21.5%)
 The consequences of stroke are socioeconomic
 Therefore, in light of this disease burden, prevention of initial
and recurrent stroke is a major priority for healthcare providers
STROKE IS MORE FREQUENT THAN AMI
Gentil, A et al. J Neurol Neurosurg Psychiatry 2009;80:1006-1011C
STROKE AND AMI MORTALITY
ARE SIMILAR
Copyright ©2009 BMJ Publishing Group Ltd.
Gentil, A et al. J Neurol Neurosurg Psychiatry 2009;80:1006-1011C
RISK FACTORS FOR STROKE
SYSTOLIC BLOOD PRESSURE
AND RISK OF STROKE
Lewis et al. Lancet 2002;360:1903–13
CAN WE EXTRAPOLATE DATA
FROM PRIMARY PREVENTION
TRIALS TO SECONDARY
PREVENTION IN STROKE ?
DECREASING BP DECREASE
THE RISK OF STROKE
Law, M R et al. BMJ 2009;338:b1665
ANTIHYPERTENSIVES DO NOT HAVE THE SAME
BENEFICIAL EFFECT ON PREVENTING STROKE
Law, M R et al. BMJ 2009;338:b1665
PROGRESS
Lancet 2001; 358:1033
ANTIHYPERTENSIVE THERAPY AFTER STROKE
PROFESS TRIAL
N Engl J Med 2008; 359 (12) : 1225-37
POST STROKE TRIAL
 ACCESS: candesartan, post acute STROKE, positive
but pilot study
 SCAST: candesartan, negative.
 PROFESS: telmisartan, post stroke negative
 MOSES: eprosartan, post stroke only positive trial with
an active comparator, benefits beyond simple BP
reduction.
 Primary endpoint:
 Total mortality plus total number of
cardiovascular and cerebrovascular events
 Secondary endpoints:
 Change in mental capacity and functional status
(Barthel Index and Rankin Scale)
 Individual elements of the combined primary
endpoint
 Mean follow-up:
 2.5 years
29 in total:
14 withdrew consent prior
to first intake of study drug
1 without known vital status
14 lost for follow-up monitoring
24 in total:
10 withdrew consent prior to
first intake of study drug
2 without known vital status
12 lost for follow-up monitoring
1,405 patients eligible for randomization
710 assigned to
eprosartan-based
regimen
695 assigned to
nitrendipine-based
regimen
681 available for intention-
to-treat analyses
671 available for intention-
to-treat analyses
Schrader J. et al. Stroke 2005;36:1218-1226
Schrader J. et al. Stroke 2005;36:1218-1226
25%
Primary end points
First cardiovascular events
0
0.05
0.1
0.15
0.2
0.25
0 400 800 1200 1600
Eprosartan
Nitrendipine
Risk
reduction
30%
P=0.03
Schrader J, et al. Stroke 2005; 36: 1218
CHF: 34%
MI: 10%
Is it BP reduction effect ?
Blood pressure Blood pressure
Riskofcoronaryheartdisease
Nitrendipine
Nitrendipine
Teveten
Teveten
-25%vs
CCB
-31%vs CCB
)1st time occurrence(
Risk of Stroke and CHD – MOSES StudyRisk of Stroke and CHD – MOSES Study
Benefits beyond BP LoweringBenefits beyond BP Lowering
Riskofcerebrovascularevents
Adverse Remodeling of the VasculatureAdverse Remodeling of the Vasculature
Alpha-1
vasoconstriction
Ang II
Doxazosin
Prazosin
Eprosartan
NE
Eprosartan
(ARBs)
Vasoconstriction
Vasoconstriction
Media hypertrophy
Collagen deposition
Dual mechanism of
action
CONCLUSIONS
 Cerebrovascular health protection is cardiovascular
prevention
 Prevention is primary, secondary prevention of stroke but
also dementia and global cardiovascular protection
 Evidence based approach:
 Eprosartan
 Efficient in BP reduction
 Specific and dual mode of action
 Prevention of cardiovascular and cerebrovascular
Health
Nhi teveten

More Related Content

What's hot

Hypertension lecture prof zak (1)
Hypertension lecture prof zak (1)Hypertension lecture prof zak (1)
Hypertension lecture prof zak (1)
Professor M Zak Khalil, MD, MRCP (UK), FACC, FESC
 
Whelton sprint(1)
Whelton sprint(1)Whelton sprint(1)
Whelton sprint(1)
Jose Mejias Melendez
 
Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...MedicineAndFamily
 
Update in hypertension management
Update in hypertension managementUpdate in hypertension management
Update in hypertension management
Tarek Khalil
 
An Evidence Based Approach To Hypertension
An Evidence Based Approach To HypertensionAn Evidence Based Approach To Hypertension
An Evidence Based Approach To HypertensionAline Chammas
 
Cozaar
CozaarCozaar
Guias esh 2013
Guias esh 2013Guias esh 2013
Guias esh 2013
clinicosha
 
Current management of hypertension DR. ANKIT JAIN AIIMS
Current management of hypertension DR. ANKIT JAIN AIIMSCurrent management of hypertension DR. ANKIT JAIN AIIMS
Current management of hypertension DR. ANKIT JAIN AIIMS
Ankit Jain
 
Progress study natrilix sr
Progress study natrilix srProgress study natrilix sr
Progress study natrilix sr
austinr3
 
ARB in the management of Hypertension
ARB in the management of HypertensionARB in the management of Hypertension
ARB in the management of Hypertension
Mohammad Arifur Rahman
 
14.09 bp management in diabetes
14.09 bp management in diabetes14.09 bp management in diabetes
14.09 bp management in diabetesRajeev Agarwala
 
Hypertension 2014 update
Hypertension 2014 updateHypertension 2014 update
Hypertension 2014 update
abualbd
 
Management of hypertension in diabetes
Management of hypertension in diabetesManagement of hypertension in diabetes
Management of hypertension in diabetes
Dr Karthik Balachandran
 
Cardio renal care-An integated best Practice Approch
Cardio renal care-An integated best Practice ApprochCardio renal care-An integated best Practice Approch
Cardio renal care-An integated best Practice Approch
drucsamal
 
6122 htn lp_01.12.06
6122 htn lp_01.12.066122 htn lp_01.12.06
6122 htn lp_01.12.06Dr P Deepak
 
Update 2015- What's New From Cardiology Main Congresses JNUC4 2015 final
Update 2015- What's New From Cardiology Main Congresses JNUC4 2015 finalUpdate 2015- What's New From Cardiology Main Congresses JNUC4 2015 final
Update 2015- What's New From Cardiology Main Congresses JNUC4 2015 final
Nicolas Peschanski, MD, PhD
 
Management Of Hypertension in diabetes- 2009
Management Of Hypertension in diabetes- 2009Management Of Hypertension in diabetes- 2009
Management Of Hypertension in diabetes- 2009
mondy19
 
Role of aci ccb in htn management
Role of aci ccb in htn managementRole of aci ccb in htn management
Role of aci ccb in htn management
Dr. Adel El Naggar
 

What's hot (20)

Hypertension lecture prof zak (1)
Hypertension lecture prof zak (1)Hypertension lecture prof zak (1)
Hypertension lecture prof zak (1)
 
Whelton sprint(1)
Whelton sprint(1)Whelton sprint(1)
Whelton sprint(1)
 
Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...Hypertension: New Concepts, Guidelines, and Clinical Management 	 Hypertensio...
Hypertension: New Concepts, Guidelines, and Clinical Management Hypertensio...
 
Update in hypertension management
Update in hypertension managementUpdate in hypertension management
Update in hypertension management
 
An Evidence Based Approach To Hypertension
An Evidence Based Approach To HypertensionAn Evidence Based Approach To Hypertension
An Evidence Based Approach To Hypertension
 
Cozaar
CozaarCozaar
Cozaar
 
Guias esh 2013
Guias esh 2013Guias esh 2013
Guias esh 2013
 
Current management of hypertension DR. ANKIT JAIN AIIMS
Current management of hypertension DR. ANKIT JAIN AIIMSCurrent management of hypertension DR. ANKIT JAIN AIIMS
Current management of hypertension DR. ANKIT JAIN AIIMS
 
S cárdio renal
S cárdio renalS cárdio renal
S cárdio renal
 
Progress study natrilix sr
Progress study natrilix srProgress study natrilix sr
Progress study natrilix sr
 
ARB in the management of Hypertension
ARB in the management of HypertensionARB in the management of Hypertension
ARB in the management of Hypertension
 
14.09 bp management in diabetes
14.09 bp management in diabetes14.09 bp management in diabetes
14.09 bp management in diabetes
 
Hypertension 2014 update
Hypertension 2014 updateHypertension 2014 update
Hypertension 2014 update
 
Management of hypertension in diabetes
Management of hypertension in diabetesManagement of hypertension in diabetes
Management of hypertension in diabetes
 
Cardio renal care-An integated best Practice Approch
Cardio renal care-An integated best Practice ApprochCardio renal care-An integated best Practice Approch
Cardio renal care-An integated best Practice Approch
 
6122 htn lp_01.12.06
6122 htn lp_01.12.066122 htn lp_01.12.06
6122 htn lp_01.12.06
 
Update 2015- What's New From Cardiology Main Congresses JNUC4 2015 final
Update 2015- What's New From Cardiology Main Congresses JNUC4 2015 finalUpdate 2015- What's New From Cardiology Main Congresses JNUC4 2015 final
Update 2015- What's New From Cardiology Main Congresses JNUC4 2015 final
 
Hypertension
HypertensionHypertension
Hypertension
 
Management Of Hypertension in diabetes- 2009
Management Of Hypertension in diabetes- 2009Management Of Hypertension in diabetes- 2009
Management Of Hypertension in diabetes- 2009
 
Role of aci ccb in htn management
Role of aci ccb in htn managementRole of aci ccb in htn management
Role of aci ccb in htn management
 

Viewers also liked

NEWS & VIEWS, HEC Pakistan, December 2011
NEWS & VIEWS, HEC Pakistan, December 2011NEWS & VIEWS, HEC Pakistan, December 2011
NEWS & VIEWS, HEC Pakistan, December 2011Shujaul Mulk Khan
 
Tse copyright 2014
Tse copyright 2014Tse copyright 2014
Tse copyright 2014
Valeryia Kazheunikava
 
Catheter Markets
Catheter MarketsCatheter Markets
Catheter Markets
ReportLinker.com
 
คู่มือ
คู่มือคู่มือ
คู่มือaispretty
 
Clinical Information Systems
Clinical Information SystemsClinical Information Systems
Clinical Information Systems
Nawanan Theera-Ampornpunt
 
Blink credential 7 2012
Blink credential 7 2012Blink credential 7 2012
Blink credential 7 2012Khuong Cuong
 
2010 BDPA Technology Conference Guide
2010 BDPA Technology Conference Guide2010 BDPA Technology Conference Guide
2010 BDPA Technology Conference Guide
BDPA Education and Technology Foundation
 
2012 deep research report on china influenza vaccine industry
2012 deep research report on china influenza vaccine industry2012 deep research report on china influenza vaccine industry
2012 deep research report on china influenza vaccine industrysmarter2011
 
รายชื่อหนังสือที่จัดซื้อใหม่ประจำเดือน มกราคม 2555
รายชื่อหนังสือที่จัดซื้อใหม่ประจำเดือน มกราคม 2555รายชื่อหนังสือที่จัดซื้อใหม่ประจำเดือน มกราคม 2555
รายชื่อหนังสือที่จัดซื้อใหม่ประจำเดือน มกราคม 2555
Humanities Information Center
 
BDPA Corporate Sponsors (Dec 2012)
BDPA Corporate Sponsors (Dec 2012)BDPA Corporate Sponsors (Dec 2012)
BDPA Corporate Sponsors (Dec 2012)
BDPA Education and Technology Foundation
 
Diagnostic electrophysiology (ep) catheters global trends, estimates and fo...
Diagnostic electrophysiology (ep) catheters   global trends, estimates and fo...Diagnostic electrophysiology (ep) catheters   global trends, estimates and fo...
Diagnostic electrophysiology (ep) catheters global trends, estimates and fo...Research Hub
 
Spatial analysis of topography and river watershed factors for leptospirosis ...
Spatial analysis of topography and river watershed factors for leptospirosis ...Spatial analysis of topography and river watershed factors for leptospirosis ...
Spatial analysis of topography and river watershed factors for leptospirosis ...
ILRI
 
biomed.in.th
biomed.in.thbiomed.in.th
biomed.in.th
Pongsak Sarapukdee
 
Auto pollution diagnostics software
Auto pollution diagnostics softwareAuto pollution diagnostics software
Auto pollution diagnostics software
christopher russell
 

Viewers also liked (20)

NEWS & VIEWS, HEC Pakistan, December 2011
NEWS & VIEWS, HEC Pakistan, December 2011NEWS & VIEWS, HEC Pakistan, December 2011
NEWS & VIEWS, HEC Pakistan, December 2011
 
Tse copyright 2014
Tse copyright 2014Tse copyright 2014
Tse copyright 2014
 
Silvers, David CV
Silvers, David CVSilvers, David CV
Silvers, David CV
 
Catheter Markets
Catheter MarketsCatheter Markets
Catheter Markets
 
Ovarian Cancer: Three sides of the Story: Yuko Abbott, LCSW
Ovarian Cancer: Three sides of the Story: Yuko Abbott, LCSW  Ovarian Cancer: Three sides of the Story: Yuko Abbott, LCSW
Ovarian Cancer: Three sides of the Story: Yuko Abbott, LCSW
 
คู่มือ
คู่มือคู่มือ
คู่มือ
 
Clinical Information Systems
Clinical Information SystemsClinical Information Systems
Clinical Information Systems
 
Blink credential 7 2012
Blink credential 7 2012Blink credential 7 2012
Blink credential 7 2012
 
2010 BDPA Technology Conference Guide
2010 BDPA Technology Conference Guide2010 BDPA Technology Conference Guide
2010 BDPA Technology Conference Guide
 
2012 deep research report on china influenza vaccine industry
2012 deep research report on china influenza vaccine industry2012 deep research report on china influenza vaccine industry
2012 deep research report on china influenza vaccine industry
 
Shockในศัลยกรรม
ShockในศัลยกรรมShockในศัลยกรรม
Shockในศัลยกรรม
 
รายชื่อหนังสือที่จัดซื้อใหม่ประจำเดือน มกราคม 2555
รายชื่อหนังสือที่จัดซื้อใหม่ประจำเดือน มกราคม 2555รายชื่อหนังสือที่จัดซื้อใหม่ประจำเดือน มกราคม 2555
รายชื่อหนังสือที่จัดซื้อใหม่ประจำเดือน มกราคม 2555
 
Goverment gazette 2555
Goverment gazette 2555Goverment gazette 2555
Goverment gazette 2555
 
Lydia Rabinovich Resume
Lydia Rabinovich ResumeLydia Rabinovich Resume
Lydia Rabinovich Resume
 
BDPA Corporate Sponsors (Dec 2012)
BDPA Corporate Sponsors (Dec 2012)BDPA Corporate Sponsors (Dec 2012)
BDPA Corporate Sponsors (Dec 2012)
 
Diagnostic electrophysiology (ep) catheters global trends, estimates and fo...
Diagnostic electrophysiology (ep) catheters   global trends, estimates and fo...Diagnostic electrophysiology (ep) catheters   global trends, estimates and fo...
Diagnostic electrophysiology (ep) catheters global trends, estimates and fo...
 
Spatial analysis of topography and river watershed factors for leptospirosis ...
Spatial analysis of topography and river watershed factors for leptospirosis ...Spatial analysis of topography and river watershed factors for leptospirosis ...
Spatial analysis of topography and river watershed factors for leptospirosis ...
 
biomed.in.th
biomed.in.thbiomed.in.th
biomed.in.th
 
Auto pollution diagnostics software
Auto pollution diagnostics softwareAuto pollution diagnostics software
Auto pollution diagnostics software
 
Epilepsy
EpilepsyEpilepsy
Epilepsy
 

Similar to Nhi teveten

State of art cardiovascular prevention in diabetes - helsinki april 2018
State of art   cardiovascular prevention in diabetes - helsinki april 2018State of art   cardiovascular prevention in diabetes - helsinki april 2018
State of art cardiovascular prevention in diabetes - helsinki april 2018
SoM
 
Prof .Aziz-ur-Rehman
Prof .Aziz-ur-RehmanProf .Aziz-ur-Rehman
Prof .Aziz-ur-RehmanPk Doctors
 
Coronary Artery Disease in Epidemic Proportions in the Indian Subcontinent
Coronary Artery Disease in Epidemic Proportions in the Indian SubcontinentCoronary Artery Disease in Epidemic Proportions in the Indian Subcontinent
Coronary Artery Disease in Epidemic Proportions in the Indian Subcontinent
drmjavedakhtar
 
How Should One Decide Whom to Treat for Hypertension? How Should One Decide...
How Should One Decide Whom to Treat for Hypertension? 	 How Should One Decide...How Should One Decide Whom to Treat for Hypertension? 	 How Should One Decide...
How Should One Decide Whom to Treat for Hypertension? How Should One Decide...MedicineAndHealthUSA
 
Goals_and_Rationale_ASH_Presentation_2012
Goals_and_Rationale_ASH_Presentation_2012Goals_and_Rationale_ASH_Presentation_2012
Goals_and_Rationale_ASH_Presentation_2012Heather Anderson, MS
 
Hypertension
HypertensionHypertension
Hypertension
Anac09
 
download-key-lessons-on-ldl-c-and-cv-risk.pptx
download-key-lessons-on-ldl-c-and-cv-risk.pptxdownload-key-lessons-on-ldl-c-and-cv-risk.pptx
download-key-lessons-on-ldl-c-and-cv-risk.pptx
UmaShanksr
 
Mubashar A Choudry MD | Effects of statin or usual care on outcomes
Mubashar A Choudry MD | Effects of statin or usual care on outcomesMubashar A Choudry MD | Effects of statin or usual care on outcomes
Mubashar A Choudry MD | Effects of statin or usual care on outcomes
Mubashar A Choudry MD
 
Telsarta-A final-01-04-16
Telsarta-A  final-01-04-16Telsarta-A  final-01-04-16
Telsarta-A final-01-04-16Muhammad Aun
 
Bd1e Management Of Heart Failure
Bd1e Management Of Heart FailureBd1e Management Of Heart Failure
Bd1e Management Of Heart Failuremario valenza
 
SPRINT trial
SPRINT trialSPRINT trial
SPRINT trial
Dr Jyotirmoy Paul
 
Htn1
Htn1Htn1
Htn1
hospital
 
C:\Cema\HipertensióN Arterial Curso 2008 2
C:\Cema\HipertensióN Arterial Curso 2008 2C:\Cema\HipertensióN Arterial Curso 2008 2
C:\Cema\HipertensióN Arterial Curso 2008 2gueste2c1102
 
Rafael Carmena Rodriguéz en Clinicardio09: Novedades en práctica clínica sobr...
Rafael Carmena Rodriguéz en Clinicardio09: Novedades en práctica clínica sobr...Rafael Carmena Rodriguéz en Clinicardio09: Novedades en práctica clínica sobr...
Rafael Carmena Rodriguéz en Clinicardio09: Novedades en práctica clínica sobr...
Sociedad Española de Cardiología
 
Hypertension update,ARB
Hypertension update,ARBHypertension update,ARB
Hypertension update,ARBko ko
 
The Importance of 24-H BP Control 2017(1).pptx
The Importance of 24-H BP Control 2017(1).pptxThe Importance of 24-H BP Control 2017(1).pptx
The Importance of 24-H BP Control 2017(1).pptx
dinipratiwi27
 
Evolocumab Amgan sept 2020.Dr adel sallam.pptx
Evolocumab  Amgan sept 2020.Dr adel sallam.pptxEvolocumab  Amgan sept 2020.Dr adel sallam.pptx
Evolocumab Amgan sept 2020.Dr adel sallam.pptx
AdelSALLAM4
 

Similar to Nhi teveten (20)

State of art cardiovascular prevention in diabetes - helsinki april 2018
State of art   cardiovascular prevention in diabetes - helsinki april 2018State of art   cardiovascular prevention in diabetes - helsinki april 2018
State of art cardiovascular prevention in diabetes - helsinki april 2018
 
Prof .Aziz-ur-Rehman
Prof .Aziz-ur-RehmanProf .Aziz-ur-Rehman
Prof .Aziz-ur-Rehman
 
Coronary Artery Disease in Epidemic Proportions in the Indian Subcontinent
Coronary Artery Disease in Epidemic Proportions in the Indian SubcontinentCoronary Artery Disease in Epidemic Proportions in the Indian Subcontinent
Coronary Artery Disease in Epidemic Proportions in the Indian Subcontinent
 
How Should One Decide Whom to Treat for Hypertension? How Should One Decide...
How Should One Decide Whom to Treat for Hypertension? 	 How Should One Decide...How Should One Decide Whom to Treat for Hypertension? 	 How Should One Decide...
How Should One Decide Whom to Treat for Hypertension? How Should One Decide...
 
Goals_and_Rationale_ASH_Presentation_2012
Goals_and_Rationale_ASH_Presentation_2012Goals_and_Rationale_ASH_Presentation_2012
Goals_and_Rationale_ASH_Presentation_2012
 
Hypertension
HypertensionHypertension
Hypertension
 
Supra Rx Dose of ARBs
Supra Rx Dose of ARBsSupra Rx Dose of ARBs
Supra Rx Dose of ARBs
 
download-key-lessons-on-ldl-c-and-cv-risk.pptx
download-key-lessons-on-ldl-c-and-cv-risk.pptxdownload-key-lessons-on-ldl-c-and-cv-risk.pptx
download-key-lessons-on-ldl-c-and-cv-risk.pptx
 
Mubashar A Choudry MD | Effects of statin or usual care on outcomes
Mubashar A Choudry MD | Effects of statin or usual care on outcomesMubashar A Choudry MD | Effects of statin or usual care on outcomes
Mubashar A Choudry MD | Effects of statin or usual care on outcomes
 
Telsarta-A final-01-04-16
Telsarta-A  final-01-04-16Telsarta-A  final-01-04-16
Telsarta-A final-01-04-16
 
Diabetes Care Alphabet Strategy
Diabetes Care Alphabet StrategyDiabetes Care Alphabet Strategy
Diabetes Care Alphabet Strategy
 
Bd1e Management Of Heart Failure
Bd1e Management Of Heart FailureBd1e Management Of Heart Failure
Bd1e Management Of Heart Failure
 
SPRINT trial
SPRINT trialSPRINT trial
SPRINT trial
 
Htn1
Htn1Htn1
Htn1
 
C:\Cema\HipertensióN Arterial Curso 2008 2
C:\Cema\HipertensióN Arterial Curso 2008 2C:\Cema\HipertensióN Arterial Curso 2008 2
C:\Cema\HipertensióN Arterial Curso 2008 2
 
Rafael Carmena Rodriguéz en Clinicardio09: Novedades en práctica clínica sobr...
Rafael Carmena Rodriguéz en Clinicardio09: Novedades en práctica clínica sobr...Rafael Carmena Rodriguéz en Clinicardio09: Novedades en práctica clínica sobr...
Rafael Carmena Rodriguéz en Clinicardio09: Novedades en práctica clínica sobr...
 
Chf
ChfChf
Chf
 
Hypertension update,ARB
Hypertension update,ARBHypertension update,ARB
Hypertension update,ARB
 
The Importance of 24-H BP Control 2017(1).pptx
The Importance of 24-H BP Control 2017(1).pptxThe Importance of 24-H BP Control 2017(1).pptx
The Importance of 24-H BP Control 2017(1).pptx
 
Evolocumab Amgan sept 2020.Dr adel sallam.pptx
Evolocumab  Amgan sept 2020.Dr adel sallam.pptxEvolocumab  Amgan sept 2020.Dr adel sallam.pptx
Evolocumab Amgan sept 2020.Dr adel sallam.pptx
 

More from Amir Mahmoud

Asthma 2
Asthma 2Asthma 2
Asthma 2
Amir Mahmoud
 
Asthma
AsthmaAsthma
Asthma
Amir Mahmoud
 
Management of dyslipidemia
Management of dyslipidemiaManagement of dyslipidemia
Management of dyslipidemia
Amir Mahmoud
 
Cancer cervix screening
Cancer cervix screeningCancer cervix screening
Cancer cervix screening
Amir Mahmoud
 
Osteoprosis
OsteoprosisOsteoprosis
Osteoprosis
Amir Mahmoud
 
R2 management of menstrual disordersll
R2 management of menstrual disordersllR2 management of menstrual disordersll
R2 management of menstrual disordersllAmir Mahmoud
 
Menstrual disorders
Menstrual disordersMenstrual disorders
Menstrual disorders
Amir Mahmoud
 
R2 diagnosis and management of menstrual disordersll
R2 diagnosis and management of menstrual disordersllR2 diagnosis and management of menstrual disordersll
R2 diagnosis and management of menstrual disordersll
Amir Mahmoud
 
Adultvaccinationy 121010201616-phpapp02
Adultvaccinationy 121010201616-phpapp02Adultvaccinationy 121010201616-phpapp02
Adultvaccinationy 121010201616-phpapp02
Amir Mahmoud
 
Behavioralproblemsinchildren 140410004329-phpapp02
Behavioralproblemsinchildren 140410004329-phpapp02Behavioralproblemsinchildren 140410004329-phpapp02
Behavioralproblemsinchildren 140410004329-phpapp02
Amir Mahmoud
 
Sexually transmitted-infections2919
Sexually transmitted-infections2919Sexually transmitted-infections2919
Sexually transmitted-infections2919
Amir Mahmoud
 
Critical appraisal diagnostic
Critical appraisal diagnosticCritical appraisal diagnostic
Critical appraisal diagnostic
Amir Mahmoud
 
Fac 4-chronis-tuscano
Fac 4-chronis-tuscanoFac 4-chronis-tuscano
Fac 4-chronis-tuscano
Amir Mahmoud
 
Attention deficit-hyperactivity-disorder-(adhd)
Attention deficit-hyperactivity-disorder-(adhd)Attention deficit-hyperactivity-disorder-(adhd)
Attention deficit-hyperactivity-disorder-(adhd)
Amir Mahmoud
 
Adhd webinar wolraich
Adhd webinar wolraichAdhd webinar wolraich
Adhd webinar wolraich
Amir Mahmoud
 
Aph and pph
Aph and pphAph and pph
Aph and pph
Amir Mahmoud
 
audiometry
audiometryaudiometry
audiometry
Amir Mahmoud
 
Reading an audiogram
Reading an audiogramReading an audiogram
Reading an audiogram
Amir Mahmoud
 
Treatment of asthma
Treatment of asthmaTreatment of asthma
Treatment of asthma
Amir Mahmoud
 
Investigation of TB contacts
Investigation of TB contactsInvestigation of TB contacts
Investigation of TB contacts
Amir Mahmoud
 

More from Amir Mahmoud (20)

Asthma 2
Asthma 2Asthma 2
Asthma 2
 
Asthma
AsthmaAsthma
Asthma
 
Management of dyslipidemia
Management of dyslipidemiaManagement of dyslipidemia
Management of dyslipidemia
 
Cancer cervix screening
Cancer cervix screeningCancer cervix screening
Cancer cervix screening
 
Osteoprosis
OsteoprosisOsteoprosis
Osteoprosis
 
R2 management of menstrual disordersll
R2 management of menstrual disordersllR2 management of menstrual disordersll
R2 management of menstrual disordersll
 
Menstrual disorders
Menstrual disordersMenstrual disorders
Menstrual disorders
 
R2 diagnosis and management of menstrual disordersll
R2 diagnosis and management of menstrual disordersllR2 diagnosis and management of menstrual disordersll
R2 diagnosis and management of menstrual disordersll
 
Adultvaccinationy 121010201616-phpapp02
Adultvaccinationy 121010201616-phpapp02Adultvaccinationy 121010201616-phpapp02
Adultvaccinationy 121010201616-phpapp02
 
Behavioralproblemsinchildren 140410004329-phpapp02
Behavioralproblemsinchildren 140410004329-phpapp02Behavioralproblemsinchildren 140410004329-phpapp02
Behavioralproblemsinchildren 140410004329-phpapp02
 
Sexually transmitted-infections2919
Sexually transmitted-infections2919Sexually transmitted-infections2919
Sexually transmitted-infections2919
 
Critical appraisal diagnostic
Critical appraisal diagnosticCritical appraisal diagnostic
Critical appraisal diagnostic
 
Fac 4-chronis-tuscano
Fac 4-chronis-tuscanoFac 4-chronis-tuscano
Fac 4-chronis-tuscano
 
Attention deficit-hyperactivity-disorder-(adhd)
Attention deficit-hyperactivity-disorder-(adhd)Attention deficit-hyperactivity-disorder-(adhd)
Attention deficit-hyperactivity-disorder-(adhd)
 
Adhd webinar wolraich
Adhd webinar wolraichAdhd webinar wolraich
Adhd webinar wolraich
 
Aph and pph
Aph and pphAph and pph
Aph and pph
 
audiometry
audiometryaudiometry
audiometry
 
Reading an audiogram
Reading an audiogramReading an audiogram
Reading an audiogram
 
Treatment of asthma
Treatment of asthmaTreatment of asthma
Treatment of asthma
 
Investigation of TB contacts
Investigation of TB contactsInvestigation of TB contacts
Investigation of TB contacts
 

Recently uploaded

BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
Krishan Murari
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Prof. Marcus Renato de Carvalho
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
vimalpl1234
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
pal078100
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
Sapna Thakur
 
Light House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat EuropeLight House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat Europe
Lighthouse Retreat
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
kevinkariuki227
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
Jim Jacob Roy
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
MedicoseAcademics
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
MedicoseAcademics
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
FFragrant
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
NephroTube - Dr.Gawad
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
GL Anaacs
 
Pictures of Superficial & Deep Fascia.ppt.pdf
Pictures of Superficial & Deep Fascia.ppt.pdfPictures of Superficial & Deep Fascia.ppt.pdf
Pictures of Superficial & Deep Fascia.ppt.pdf
Dr. Rabia Inam Gandapore
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Dr. Madduru Muni Haritha
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
aljamhori teaching hospital
 
Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Pharma Pcd Franchise in Jharkhand - Yodley LifesciencesPharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Yodley Lifesciences
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Savita Shen $i11
 

Recently uploaded (20)

BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
 
Light House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat EuropeLight House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat Europe
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
 
Non-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdfNon-respiratory Functions of the Lungs.pdf
Non-respiratory Functions of the Lungs.pdf
 
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
 
Pictures of Superficial & Deep Fascia.ppt.pdf
Pictures of Superficial & Deep Fascia.ppt.pdfPictures of Superficial & Deep Fascia.ppt.pdf
Pictures of Superficial & Deep Fascia.ppt.pdf
 
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradeshBasavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 
Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Pharma Pcd Franchise in Jharkhand - Yodley LifesciencesPharma Pcd Franchise in Jharkhand - Yodley Lifesciences
Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
 

Nhi teveten

  • 1. Cardiovascular and Cerebrovascular health in the management of hypertensive patients
  • 2. Not all ARBs looks after your patient heart as well as his mind
  • 3. Cardiovascular Disease: A Worldwide Epidemic World Health Organization Burden of Disease Estimates 2002. 0 5 10 15 20 25 30 35 40 45 50 CVDs Infectious/parasitic diseases Malignant neoplasms Respiratory infections Respiratory diseases Unintentional injuries Perinatal conditions Digestive diseases Intentional injuries Neuropsychiatric conditions Diabetes mellitus Cause of death Worldwide Developed world CVD is responsible for one third of all deaths worldwide and almost half of all deaths in the developed world
  • 4. Contribution of Risk Factors to Burden of Disease Mortality* *Based on The World Health Report 2003.*Based on The World Health Report 2003. Yach et al.Yach et al. JAMAJAMA. 2004;291:2616-2622.. 2004;291:2616-2622. 0 5 10 15 20 Percentage of Mortality Attributable to Risk Factors DevelopingDeveloping countriescountries DevelopedDeveloped countriescountries Blood pressureBlood pressure TobaccoTobacco UnderweightUnderweight AlcoholAlcohol CholesterolCholesterol Unsafe sexUnsafe sex OverweightOverweight Unsafe water, sanitation,Unsafe water, sanitation, hygienehygiene Low fruit and vegetableLow fruit and vegetable intakeintake Indoor smoke from solid fuelsIndoor smoke from solid fuels Physical inactivityPhysical inactivity
  • 5. Hypertension: A Growing Problem Prevalence (%) United StatesUnited States77 EgyptEgypt99 JapanJapan88 ItalyItaly77 SwedenSweden77 EnglandEngland77 SpainSpain77 FinlandFinland77 GermanyGermany77 00 1010 2020 3030 4040 5050 TaiwanTaiwan99 CanadaCanada77 South KoreaSouth Korea99 *Defined as systolic/diastolic blood pressure*Defined as systolic/diastolic blood pressure ≥≥140/90, (140/90, (≥≥160/95 for Taiwan)160/95 for Taiwan) or receiving treatment.or receiving treatment. †† South Korea is defined as men, aged 30 to 59.South Korea is defined as men, aged 30 to 59. 7. Wolf-Maier et al.7. Wolf-Maier et al. JAMAJAMA. 2003;289:2363-2369; 8. Data on file. Pfizer Inc, New York, NY;. 2003;289:2363-2369; 8. Data on file. Pfizer Inc, New York, NY; 9.9. WHO Collaborating Centre on Surveillance of Cardiovascular Disease Web site. Available at: www.cvdinfobase.ca. Accessed February 22, 2005.WHO Collaborating Centre on Surveillance of Cardiovascular Disease Web site. Available at: www.cvdinfobase.ca. Accessed February 22, 2005.
  • 6. Lewington et al. Lancet 2002 ; 360 : 1903–13. CARDIOVASCULAR MORTALITY DOUBLES FOR EVERY INCREMENT IN SBP/DBP OF 20/10 mm Hg
  • 7.  Meta-analysis of 61 prospective, observational studies  1 million adults  12.7 million person-years BENEFITS OF BP DECREASE Lewington S, et al. Lancet. 2002;360:1903-1913.
  • 8. Effect of antihypertensive therapy on all CV events: Comparison of more or less intensive BP control Relative risk (95% CIs) 1.0 1.25 More intensive BP control better Less intensive BP control better 0.5 Stroke Coronary heart disease Heart failure Major CV events CV death Total mortality BPLTTC Lancet 2003
  • 9. Benefits of Lowering BP Average Percent ReductionAverage Percent Reduction Stroke incidenceStroke incidence 35–40%35–40% Myocardial infarctionMyocardial infarction 20–25%20–25% Heart failureHeart failure 50%50%
  • 10. SBP-Associated Risks: MRFIT Adapted from Neaton JD et al. Arch Intern Med. 1992;152:56-64. SBP versus DBP in Risk of CHD Mortality Diastolic BP (mm Hg) Systolic BP (mm Hg) CHD Death Rate 100+ 90–99 80–89 75–79 70–74 <70 <120 120–139 140–159 160+ 48.3 20.6 10.3 11.8 8.8 8.5 9.2 23.8 16.9 13.9 12.8 12.6 11.8 31.0 25.5 24.6 25.3 25.2 24.9 37.4 34.7 43.8 38.1 80.6
  • 11. Pulse Pressure • Increase in pulse pressure (PP) indicates greater stiffness in large conduit arteries, primarily the thoracic aorta. • PP may be a better marker of increased CV risk than either systolic BP or diastolic BP alone in older persons. PP = SBP – DBPPP = SBP – DBP
  • 12. 2007 ESH/ESC Hypertension Guidelines2007 ESH/ESC Hypertension Guidelines First Choice Drug TreatmentFirst Choice Drug Treatment  DiureticsDiuretics  ACE-inhibitorsACE-inhibitors  Calcium antagonistsCalcium antagonists  Angiotensin receptor antagonistsAngiotensin receptor antagonists  Beta-blockersBeta-blockers
  • 13. Rationale for Use of ARB’s in Hypertension
  • 14. Rationale for Use of ARB’s in Hypertension • Specific blockade of the renin-angiotensin- aldosterone system provides: – More complete blockade of BP response to angiotensin II (specific for ATII receptor blockade) – Reduced potential for target organ damage – Reduced potential for bradykinin “cough” – Best tolerability (specific for ATII receptor blockade) – Some studies suggest a reduced risk of vascular events compared with other BP lowering regimens Guidelines recognize the additive positive effect of ARBs in hypertensives with: • Type 2 diabetes • End-organ disease, particularly that affecting the kidney
  • 15. RR (95% CI) Favors ARB Favors Other 0.5 1.0 2.0 Relative risk 0.79 (0.69,0.90)Stroke 0.96 (0.85,1.09)CHD Heart failure 0.84 (0.72,0.97) Major CV events 0.90 (0.83,0.96) CV death 0.96 (0.85,1.08) Total mortality 0.94 (0.86,1.02) Outcome BP difference (mmHg) -2/-1 -2/-1 -2/-1 -2/-1 -2/-1 -2/-1 Angiotensin Receptor Antagonists Reduce RiskAngiotensin Receptor Antagonists Reduce Risk of Vascular Events And Total Mortalityof Vascular Events And Total Mortality BPLTTC Lancet 2003; 362: 1527-35 Based on analysis of data from the SCOPE, IDNT, RENAAL and LIFE trials
  • 16. Diuretics β-blockers Ca-antagonists ACE-Inhibitors LVMassreduction,% -16 -14 -12 -10 -8 -6 -4 -2 0 - 8% - 6% - 11% - 10% ARBs - 13% 80 randomized controlled trials; 4113 patients Meta-analysis of Randomized, Controlled Trials of LV Hypertrophy Regression in Essential Hypertension Klingbeil AU et al. Am J Med 2003; 115:41-46
  • 17. ARBs significantly increased probability of maintaining sinus rhythm 0 20 40 60 80 100 Probability of maintaining sinus rhythm (%) ARB + amiodarone Madrid A et al. Circulation p = 0.008 vs. amiodarone Amiodarone 85% 63% 159 patients with persistent atrial fibrillation were randomized159 patients with persistent atrial fibrillation were randomized to either amiodarone or amiodarone + ARBto either amiodarone or amiodarone + ARB Results are taken at 2-month follow-up visitResults are taken at 2-month follow-up visit
  • 18. Mancia G et al. J Hypertens 2007; 25:1105-1187. Antihypertensive treatment: Preferred drugs as per new European guidelines Clinical eventClinical event TreatmentTreatment Atrial fibrillationAtrial fibrillation    •RecurrentRecurrent Angiotensin receptor blockers, ACEAngiotensin receptor blockers, ACE inhibitorsinhibitors •PermanentPermanent Beta blockers, nonhydropyridineBeta blockers, nonhydropyridine calcium antagonistscalcium antagonists ESRD/proteinuriaESRD/proteinuria ACE inhibitors, angiotensin receptorACE inhibitors, angiotensin receptor blockers, loop diureticsblockers, loop diuretics PADPAD Calcium antagonistsCalcium antagonists LVH=left ventricular hypertrophy ESRD=end-stage renal disease PAD=peripheral arterial disease ISH=isolated systolic hypertension
  • 19. ESH/ESC Guidelines “A blocker of the renin- angiotensin system should be a regular component of combination treatment and the one preferred when monotherapy is sufficient”
  • 20. Others 2.2% (-13.9%) ACEi 26.9% (-4.0%) CCB 13.9% (+4.8%) DIU 15.7% (+3.0%) ARB 17.7% (+17.9%) BB 23.5% (+9.1%) Overall Hypertension Market in Egypt ARBs are most rapidly growing group Source: IMS Rx Audit MAT QIII’2007 HT Market Definition: C2, C3, C7, C8, C9
  • 22. Change in mean SBP and DBP from baseline after 8 weeks of treatment with eprosartan (600mg/day) or placebo in patients with mild-to-moderate hypertension Eprosartan vs Placebo in Mild-to-Moderate HTN -26 -17.1 -12.6 -13.5 -50 -45 -40 -35 -30 -25 -20 -15 -10 -5 0 mmHg SBP MBP DBP PP
  • 23. Sega. Blood Press 1999;8:114 ReductioninsitSBP(mmHg) p=0.025 –29.1 –21.2 –15 –25 –20 –30 0 –5 –10 ReductioninstaSBP(mmHg) p=0.032 –27.8 –20.0 –15 –25 –20 –30 0 –5 –10 Eprosartan Enalapril Eprosartan reduces sitSBP and staSBP in patients with severe hypertension
  • 24. Argenziano & Trimarco. Curr Med Res Opin 1999;15:9 <65 years (n=201) ≥65 years (n=63) 0 –2 –4 –6 –8 –10 –12 –14 –16 –18 –20 MeanchangefrombaselineinsitSBP(mmHg) Eprosartan has similar efficacy in young and elderly patients 0 –2 –4 –6 –8 –10 –12 –14 –16 –18 –20 <65 years (n=201) ≥65 years (n=63) MeanchangefrombaselineinsitDBP(mmHg)
  • 25. Puig et al. J Hypertens 1999;17:1033 ReductioninsitBP(mmHg) –18 –15 –12 –9 –6 –3 0 Diastolic Systolic –12.4 –9.6 –12.7 –10.9 0 20 40 60 80 Responserate(%) 73 53 100 Eprosartan Losartan Eprosartan is more effective than losartan in mild hypertension
  • 26. PULSE PRESSURE REDUCTION Robles NR, et al. Int J Clin Pract 2005;59(4):478-484 Reduction in mean pulse pressure, arterial pressure, SBP and DBP in a 16-week open-label study (n=566)
  • 27. Teveten effect on fibrinolytic/hemostatic variables: Comparative study to losartan In conclusion, the results indicate that 6-month monotherapy with an angiotensin II type 1 receptor blocker, eprosartan, is associated with a more favorable modification of hemostatic & fibrinolytic status than with losartan Drugs Exp Clin Res. 2004;30(3):125-32
  • 28. Effect of Teveten on cytoplasmic free calcium mobilization, platelet activation, and microparticle formation in hypertension CONCLUSIONS: Teveten significantly reduces blood pressure and normalizes undesirable changes in platelet function Am J Hypertens. 2004 Sep;17(9):757-63.
  • 29.
  • 30. CEREBROVASCULAR RISK EPIDEMIOLOGY Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.Circulation 2009;119:e21–181.  CVD is the 3rd leading cause of death in the U.S. and the first cause of long-term major disability  There are 795,000 incident strokes in the U.S. each year  8–12% of individuals die within the first 30 days of their initial stroke  Patients who survive the initial attack face an increased risk of subsequent vascular events and stroke (21.5%)  The consequences of stroke are socioeconomic  Therefore, in light of this disease burden, prevention of initial and recurrent stroke is a major priority for healthcare providers
  • 31. STROKE IS MORE FREQUENT THAN AMI Gentil, A et al. J Neurol Neurosurg Psychiatry 2009;80:1006-1011C
  • 32. STROKE AND AMI MORTALITY ARE SIMILAR Copyright ©2009 BMJ Publishing Group Ltd. Gentil, A et al. J Neurol Neurosurg Psychiatry 2009;80:1006-1011C
  • 34. SYSTOLIC BLOOD PRESSURE AND RISK OF STROKE Lewis et al. Lancet 2002;360:1903–13
  • 35. CAN WE EXTRAPOLATE DATA FROM PRIMARY PREVENTION TRIALS TO SECONDARY PREVENTION IN STROKE ?
  • 36. DECREASING BP DECREASE THE RISK OF STROKE Law, M R et al. BMJ 2009;338:b1665
  • 37. ANTIHYPERTENSIVES DO NOT HAVE THE SAME BENEFICIAL EFFECT ON PREVENTING STROKE Law, M R et al. BMJ 2009;338:b1665
  • 39. ANTIHYPERTENSIVE THERAPY AFTER STROKE PROFESS TRIAL N Engl J Med 2008; 359 (12) : 1225-37
  • 40. POST STROKE TRIAL  ACCESS: candesartan, post acute STROKE, positive but pilot study  SCAST: candesartan, negative.  PROFESS: telmisartan, post stroke negative  MOSES: eprosartan, post stroke only positive trial with an active comparator, benefits beyond simple BP reduction.
  • 41.  Primary endpoint:  Total mortality plus total number of cardiovascular and cerebrovascular events  Secondary endpoints:  Change in mental capacity and functional status (Barthel Index and Rankin Scale)  Individual elements of the combined primary endpoint  Mean follow-up:  2.5 years
  • 42. 29 in total: 14 withdrew consent prior to first intake of study drug 1 without known vital status 14 lost for follow-up monitoring 24 in total: 10 withdrew consent prior to first intake of study drug 2 without known vital status 12 lost for follow-up monitoring 1,405 patients eligible for randomization 710 assigned to eprosartan-based regimen 695 assigned to nitrendipine-based regimen 681 available for intention- to-treat analyses 671 available for intention- to-treat analyses
  • 43. Schrader J. et al. Stroke 2005;36:1218-1226
  • 44. Schrader J. et al. Stroke 2005;36:1218-1226 25% Primary end points
  • 45. First cardiovascular events 0 0.05 0.1 0.15 0.2 0.25 0 400 800 1200 1600 Eprosartan Nitrendipine Risk reduction 30% P=0.03 Schrader J, et al. Stroke 2005; 36: 1218 CHF: 34% MI: 10%
  • 46. Is it BP reduction effect ?
  • 47. Blood pressure Blood pressure Riskofcoronaryheartdisease Nitrendipine Nitrendipine Teveten Teveten -25%vs CCB -31%vs CCB )1st time occurrence( Risk of Stroke and CHD – MOSES StudyRisk of Stroke and CHD – MOSES Study Benefits beyond BP LoweringBenefits beyond BP Lowering Riskofcerebrovascularevents
  • 48. Adverse Remodeling of the VasculatureAdverse Remodeling of the Vasculature Alpha-1 vasoconstriction Ang II Doxazosin Prazosin Eprosartan NE Eprosartan (ARBs) Vasoconstriction Vasoconstriction Media hypertrophy Collagen deposition Dual mechanism of action
  • 49. CONCLUSIONS  Cerebrovascular health protection is cardiovascular prevention  Prevention is primary, secondary prevention of stroke but also dementia and global cardiovascular protection  Evidence based approach:  Eprosartan  Efficient in BP reduction  Specific and dual mode of action  Prevention of cardiovascular and cerebrovascular Health

Editor's Notes

  1. The World Health Report identified the contribution of selected risk factors to mortality worldwide in developing and developed countries. Blood pressure (BP) levels higher than optimal account for the largest percentage of mortality worldwide followed by tobacco use. Cholesterol higher than a level considered optimal is the fifth largest contributor to mortality worldwide. It is important to note that higher than optimal BP, tobacco use, and higher than optimal cholesterol are major contributors to mortality in both developing and developed countries. Risk factors such as underweight, unsafe sex, unsafe water, poor sanitation, and hygiene are overwhelmingly contributors to mortality in the developing world.
  2. The World Health Report identified the contribution of selected risk factors to mortality worldwide in developing and developed countries. Blood pressure (BP) levels higher than optimal account for the largest percentage of mortality worldwide followed by tobacco use. Cholesterol higher than a level considered optimal is the fifth largest contributor to mortality worldwide. It is important to note that higher than optimal BP, tobacco use, and higher than optimal cholesterol are major contributors to mortality in both developing and developed countries. Risk factors such as underweight, unsafe sex, unsafe water, poor sanitation, and hygiene are overwhelmingly contributors to mortality in the developing world.
  3. The World Health Report identified the contribution of selected risk factors to mortality worldwide in developing and developed countries. Blood pressure (BP) levels higher than optimal account for the largest percentage of mortality worldwide followed by tobacco use. Cholesterol higher than a level considered optimal is the fifth largest contributor to mortality worldwide. It is important to note that higher than optimal BP, tobacco use, and higher than optimal cholesterol are major contributors to mortality in both developing and developed countries. Risk factors such as underweight, unsafe sex, unsafe water, poor sanitation, and hygiene are overwhelmingly contributors to mortality in the developing world.
  4. The data from placebo-controlled trials clearly supports the benefits of treating hypertension but it should be appreciated that most (but not all) of the trials focussed upon diuretics as initial therapy. Based on their positive outcomes it was no longer considered to be ethical to perform placebo control trials. Thus for the last 10 years trials have compared alternative antihypertensive strategies using different classes of antihypertensive drugs. The philosophy underlying these trials was based upon the fact that treatment of hypertensive patients should not only consist of a reduction in blood pressure but should also focus on the effects of therapy on associated risk factors and metabolic abnormalities some of which might be deleteriously effected by the therapy itself. The question as to whether particular advantages exist for certain types of antihypertensive agent has not unequivocally been answered. However, the Blood Pressure Lowering Treatment Trialists Collaboration meta-analysis (1) clearly indicated that more intensive blood pressure lowering was associated with improvements in cardiovascular outcome, including heart failure (although heart failure did not attain statistical significance). (1) BPLTTC. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35.
  5. MRFIT showed that SBP is a stronger predictor of CHD mortality than DBP in men of all age groups except those 35 to 39 years of age. This study examined the relative risk of CHD mortality as a function of SBP and DBP in 353,340 screened men who were followed for an average of 12 years. A strong, graded relationship was evident between SBP at every level &amp;gt;110 mm Hg and death due to CHD. Differences in CHD-related mortality at various DBP levels were relatively small.24 Results from MRFIT strongly support the conclusion that SBP is a better indicator of increased CHD risk than DBP. This conclusion prompted the recent recommendation by the Coordinating Committee, National High Blood Pressure Education Program, National Heart, Lung, and Blood Institute, that SBP should “…become the principal clinical end point for the detection, evaluation, and treatment of hypertension, especially in middle-aged and older Americans.”26
  6. Hypertension is a widespread disease responsible for a considerable health care burden. Suboptimal treatment and control of hypertension is common. Blockade of the renin-angiotensin-aldosterone system with ARBs offers advantages over ACE inhibitors More complete blockade of BP response to angiotensin II (specific for ATII receptor blockade) Reduced potential for target organ damage Reduced potential for bradykinin “cough” improves tolerability (specific for ATII receptor blockade). Some studies suggest a reduced risk of vascular events compared with other BP lowering regimens. Guidelines recommend use of ARBs for hypertensive patients with end-organ disease affecting the heart and the kidney.
  7. The Blood Pressure Lowering Treatment Trialists&amp;apos; Collaboration showed that ARBs reduce the risk of vascular events such as stroke, coronary heart disease, heart failure, major cardiovascular events, cardiovascular death and total mortality when compared to other treatment regimens (placebo or other active treatment).1 Whether this benefit is due to greater blood pressure lowering (mean 2/1 mmHg) is not known. Reference Blood Pressure Lowering Treatment Trialists&amp;apos; Collaboration. Lancet 2003;362: 1527–35.
  8. GLB.IRB.06.12.01 What about the effects of antihypertensive drugs on LVH regression ? According to a meta-analysis of 80 randomized double-blind studies, angiotensin II antagonists were more effective than other classes of drugs in inducing decrease of LV mass. However, meta-analyses should be considered as hypothesis-generating rather than as definitive truth because of (a) potential methodological differences across different studies and, (b) the possibility that negative studies may go missed because unpublished or published in remote journals. However, at least two important studies supported these results: References: Klingbeil AU et al. Am J Med 2003; 115:41-46. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet 1991; 337: 867-872.
  9. By intention-to-treat analysis, the recurrence rate was lower in the amiodarone + irbesartan group. Kaplan-Meier analysis demonstrated a 2-month probability for maintaining sinus rhythm of 85% for irbesartan + amiodarone-treated patients compared with 63% for those taking amiodarone alone (p=0.008).
  10. Eprosartan reduces sitSBP and standing SBP in patients with severe hypertension A total of 118 patients with severe hypertension were randomized to eprosartan (200–400mg BID) or enalapril (10–40mg OD) in this10-week, multicentre, double-blind, parallel-group study designed to compare the antihypertensive efficacy of eprosartan with enalapril. Severe hypertension was defined as DBP 115mmHg and 125mmHg. Eprosartan was significantly (p=0.025) more effective than enalapril in reducing sitSBP, with a fall of 29.1mmHg recorded for eprosartan-treated patients, compared with 21.2mmHg for enalapril. In addition, eprosartan was significantly (p=0.032) more effective than enalapril in reducing standing SBP (staSBP) (27.8mmHg for the eprosartan group compared with 20mmHg for the enalapril group). In addition, reductions from baseline in sitDBP of 20.1mmHg and 16.2mmHg for eprosartan and enalapril, respectively, were achieved (p=0.136). Sega R. Efficacy and safety of eprosartan in patients with severe hypertension Blood Press 1999; 8: 114–121 Figure reproduced with permission
  11. Eprosartan has similar efficacy in young and elderly patients When data from a large-scale study (&amp;gt;500 patients) were analysed according to age, it was found that eprosartan proved to be effective regardless of patient’s age. Target reductions in sitDBP to either &amp;lt;90mmHg or 90–100mmHg with a decrease of &amp;gt;10mmHg from baseline were very similar in those under and over 65 years of age (13.2 and 13.9mmHg, respectively). The change from baseline in sitSBP also showed no significant difference between the two populations, with mean reductions of 16.2mmHg and 18.9mmHg for those under and over 65 years, respectively. Argenziano L, Trimarco B. Effect of eprosartan and enalapril in the treatment of elderly hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Curr Med Res Opin 1999; 15: 9–14 Figure reproduced with permission
  12. Eprosartan is more effective than losartan in mild hypertension A 4-week study was carried out to compare the effects of eprosartan (600mg OD) and losartan (50mg OD) on BP in 60 patients with mild to moderate hypertension (Puig et al, 1999). BP measurements were taken at baseline, at 2 weeks and at the end of the study. Significant reductions in BP were observed for both eprosartan and losartan. Mean reductions in DBP were 12.4 and 9.6mmHg for eprosartan and losartan, respectively, with reductions of 12.7 and 10.9mmHg in SBP. The response rate (sitDBP &amp;lt;90mmHg or a decrease of ³10mmHg from baseline) was 73% for eprosartan versus 53% for losartan. Puig JG, Mateos AF, Buno A, Ortega R, Rodriguez F, Dal-Re R. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. J Hypertens 1999; 17: 1033–1039
  13. Robles et al (2005) reported the results of a 16-week open-label study in the primary care setting, which assessed the effect of eprosartan 600mg/day on pulse pressure in patients with mild-to-moderate hypertension. Results were evaluable in 566 patients at the end of the study period. There were statistically significant reductions in mean blood pressure (-26/-13 mmHg), mean pulse pressure (-13 mmHg) and mean arterial pressure (-17.4 mmHg), all p&amp;lt;0.0001 compared with pretreatment baseline. As in the de la Sierra study, there was a statistically significant reduction in the ratio of pulse pressure/mean arterial pressure from 61% to 59%.
  14. Relative risk estimates stroke for a blood pressure reduction of 10 mm Hg systolic or 5 mm Hg diastolic in the blood pressure difference trials and in epidemiological cohort studies.
  15. Relative risk estimates of stroke in 46 drug comparison trials comparing each of the five classes of blood pressure lowering drug with any other class of drug.
  16. 20,332 pts aged more than 50 years (75 % hypertension) who recently had an ischemic stroke (within 120 days median 15 days) were randomly assigned to receive telmisartan or placebo
  17. The combined primary endpoint was a composite of total mortality plus the total number of cardiovascular and cerebrovascular events, including all recurrent events. Cerebral complications were defined as intracerebral haemorrhage, recurrence of stroke, TIAs or PRIND. Cardiovascular complications were defined as any cardiovascular event, including MI and new heart failure. Pre-defined secondary endpoints were the single components of the combined primary endpoint, as well as an assessment of functional status and cognitive function assessed by the mini mental state examination (MMSE), Barthel Index,and Rankin Scale. Mean follow-up of patients in the study was 2.5 years.
  18. A total of 1,405 patients were eligible for randomization, of whom 710 were assigned an eprosartan-based regimen and 695 a nitrendipine-based regimen. At the study end, 681 in the eprosartan and 671 in the nitrendipine groups, respectively, were eligible for analysis.
  19. SYSTOLIC AND DIASTOLIC BLOOD PRESSURE AMONG PATIENTS ASSIGNED EPROSARTAN OR NITRENDIPINE
  20. PRIMARY ENDPOINTS (TOTAL OCCURRENCE INCLUDING RECURRENT EVENTS)